Enzymatic Cascade Biocatalysis Patents: Leaders & Filing Trends 2026
Enzymatic Cascade Biocatalysis Patents: Who Holds the Cofactor Regeneration Claims
61.8% concentration. The top 5 assignees of 36 ranked account for 63 of the 102 records in scope — a narrow gate for new entrants working on cofactor regeneration or immobilized cascades. Filings peaked at 13 in 2018, dipped through the early 2020s to a low of 1 in 2021, then climbed sharply to 8 by 2024 — a +700% move over that three-year span. 2025 and 2026 figures will rise as publication catches up; they should not be read as a falloff.
- 1ANNIKKI GMBH29
- 2MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV14
- 3SANKO TEKSTIL ISLETMELERI SANAYI VE TICARET AS7
- 4UNIVERSITY OF GRONINGEN7
- 5SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES6
See the full enzymatic cascade biocatalysis analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in enzymatic cascade biocatalysis?
One assignee leads the field with 29 of the 102 records in this dataset, well ahead of the fifth-ranked assignee at 6. The top 5 of 36 ranked assignees together hold 61.8% of all records, and the top 10 hold 85.3%, so the field is concentrated at the top with a long tail of smaller filers behind it. Anyone evaluating competitive position should start by mapping the leader’s claims before assessing the rest of the tail.
Is filing activity in enzymatic cascade biocatalysis growing or slowing?
Filings grew sharply from 1 in 2021 to 8 in 2024, a +700% increase over that span, after an earlier peak of 13 in 2018 and a subsequent dip. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures in any trend chart understate real activity and should not be read as evidence of slowing. The three-year 2021-2024 window is the clearest recent growth signal available in this data.
What technical problems do these patents actually claim?
The claims cluster around the operational bottlenecks that limit cascade reactions at scale: cofactor regeneration without adding expensive NAD(P)H, enzyme compatibility across shared reaction conditions, controlling intermediate accumulation that would otherwise inhibit downstream enzymes, and reaction engineering or immobilization to sustain space-time yield outside a lab setting. C12P (fermentation and enzymatic synthesis) and C12N (microorganisms and genetic engineering) are the two dominant IPC classes, covering 80.4% and 41.2% of records respectively.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Enzymatic Cascade Biocatalysis covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.